Patient Advocacy Strategies Evolve as Genomic Advances Change Understanding of Cancer

Posted by ALCF Staff on September 8th, 2017
No Comments

The ROS1ders, are throwing their energy behind creating preclinical mouse models and cells lines that will inform drug development efforts and improve understanding of resistance mechanisms for all tumors driven by ROS1 rearrangements. Within the Global ROS1 Research Initiative, ROS1ders can donate their left-over tumor tissue after biopsies and surgeries, which a company called Champions Oncology will use to create patient-derived xenograft mouse models.

Click here to read the full article

About Guneet Walia, PhD

Dr. Guneet Walia is here to serve as your guide through what can feel like an overwhelming amount of information and jargon in lung cancer research. With her extensive background in oncology & drug development in the lab and experience working with cancer patients, she culls through the latest news to bring you the most important developments that can impact you and your disease today. If you have any questions, please don't hesitate to get in touch with Dr. Walia.

Comments are closed.